FindTrial
Sign In

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04963608
Enrollment
100
Registered
2021-07-15
Start date
2021-07-31
Completion date
2021-12-31
Last updated
2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive Advanced Breast Cancer

Brief summary

This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.

Interventions

DRUGInetetamab

8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days

Sponsors

Zhiyong Yu
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with stage IV breast cancer 2. Patients with HER2 positive status 3. Patients that received Inetetamab 4. Patients that began Inetetamab therapy prior to June 30, 2021.

Exclusion criteria

Patients treated with an investigational anticancer agent Inetetamab

Design outcomes

Primary

MeasureTime frame
Progression Free Survival(PFS)12 months
Incidences of adverse events and toxicities12 months

Contacts

Primary ContactZhiyong yu
drzhiyongyu@aliyun.com86-13355312277

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026